APPLICATIONS PUBLISHED 12 NOVEMBER 2003

Published: 1-Apr-2004

The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. T+43 1521 260 F+43 1 52126 4492


The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. T+43 1521 260 F+43 1 52126 4492

  • Oral drug delivery system
    United Pharmaceuticals Manufacturing Co 1359898*

  • Compsn and method for controlled release injections
    Cambridge Biostability 1359899*

  • A stable pharmaceutical formulation comprising torsemide modification
    Teva Pharmaceutical Industries 1359900*

  • Thermolabile liposome with controlled release temperature
    Max-Plank-Gesellschaft zur Foerderung der Wissenschaften 1359901*

  • Bimodal dry powder formulation for inhalation
    Innovata Biomed 1359902*

  • Method and device for producing thin wafers from a film of active ingredients
    LTS Lohmann Therapie-Systeme 1359903*

  • P27 prevents cellular migration
    The Trustees of Columbia University in the City of New York 1359904*

  • Use of MGLUR5 antagonists for the treatment of pruritic conditions
    Novartis 1359905*

  • Pharmaceutical compsns containing fluorinated or perfluorinated carboxylic acids
    CXR Biosciences 1359906*

  • Combination comprising an insulin secretion enhancer and an active ingredient selected from HMG-Co-A reductase inhibitors and ACE inhibitors
    Novartis 1359907*

  • Quinolines and nitrogenated derivatives thereof substituted in 4-position by a piperidine-containing moiety and their use as antibacterial agents
    SmithKline Beecham 1359908*

  • Anticancer treatment using triptolide prodrugs
    Pharmagenesis 1359909*

  • Method for treating glaucoma II B
    Alteon 1359910*

  • Method for treating fibrotic diseases or other indications IVC
    Alteon 1359911*

  • Novel methods using pyridine derivatives
    Eisai 1359912*

  • Thrombin inhibitors
    Merck 1359913*

  • Novel therapeutic use of thienyl-cyclohexylamine derivative
    Societe de Conseils de Recherches et d'Applications Scientifiques 1359914*

  • Urotensin-II receptor antagonists
    SmithKline Beecham 1359915*

  • Imidazolyl derivatives as corticotropin-releasing factor inhibitors
    Bristol-Myers Squibb 1359916*

  • Thioxazinoquinolones useful for the treatment of viral infections
    Pharmacia & Upjohn 1359917*

  • Method for treating glaucoma II B
    Alteon 1359918*

  • Method of treating substance abuse with quetiapine
    AstraZeneca 1359919*

  • You may also like